missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ THAP11 Polyclonal Antibody

Description
Immunogen sequence: QQQQSSPSAS TAQTAQLQPN LVSASAAVLL TLQATVDSSQ APGSVQPAPI TPTGEDVKPI DLTVQVEFAA AE Highest antigen sequence indentity to the following orthologs: Mouse - 85%, Rat - 88%.
This gene encodes two proteins, the SART1protein expressed in the nucleus of the majority of proliferating cells, and the SART1protein expressed in the cytosol of epithelial cancers. The SART1protein is translated by the mechanism of -1 frameshifting during posttranscriptional regulation; its full-length sequence is not published yet. The two encoded proteins are thought to be involved in the regulation of proliferation. Both proteins have tumor-rejection antigens. The SART1protein possesses tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes in cancer patients. This SART1antigen may be useful in specific immunotherapy for cancer patients and may serve as a paradigmatic tool for the diagnosis and treatment of patients with atopy. The SART1protein is found to be essential for the recruitment of the tri-snRNP to the pre-spliceosome in the spliceosome assembly pathway.
Specifications
Specifications
| Antigen | THAP11 |
| Applications | ChIP Assay, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Concentration | 0.3 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 |
| Gene | THAP11 |
| Gene Accession No. | Q96EK4 |
| Gene Alias | 2810036E22Rik; AB041579; CTG-B43a; CTG-B45d; HRIHFB2206; MNCb-2032; Ronin; THAP domain containing 11; THAP domain-containing protein 11; Thap11 |
| Gene Symbols | THAP11 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?